<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel rdf:about="http://hdl.handle.net/11434/1693">
    <title>Epworth Collection:</title>
    <link>http://hdl.handle.net/11434/1693</link>
    <description />
    <items>
      <rdf:Seq>
        <rdf:li rdf:resource="http://hdl.handle.net/11434/2394" />
        <rdf:li rdf:resource="http://hdl.handle.net/11434/2392" />
        <rdf:li rdf:resource="http://hdl.handle.net/11434/2391" />
        <rdf:li rdf:resource="http://hdl.handle.net/11434/2390" />
      </rdf:Seq>
    </items>
    <dc:date>2026-07-05T03:52:01Z</dc:date>
  </channel>
  <item rdf:about="http://hdl.handle.net/11434/2394">
    <title>Peanut allergy delabelling or oral immunotherapy (OIT) for infants at Epworth.</title>
    <link>http://hdl.handle.net/11434/2394</link>
    <description>Title: Peanut allergy delabelling or oral immunotherapy (OIT) for infants at Epworth.
Epworth Authors: Smart, Joanne; Mehr, Sam; Alhucema, Paulina; Ainsworth, John; Flanagan, Alice; Baumgartner, Joanne
Abstract: The HealthNuts study identified peanut allergy occurs in 3% of infants in Melbourne. With 70% of cases persisting beyond childhood, the traditional strategy of strict avoidance offers limited benefit and poses ongoing risk from accidental ingestion and anaphylaxis. Peanut OIT is a therapy that aims to increase an infant’s&#xD;
threshold before reacting to peanut, thereby improving safety and quality of life for parents. Infants with a confirmed peanut allergy—defined by positive SPT or serum IgE and clinical history—will be evaluated. The vast majority will undergo inpatient OFC to determine reactivity threshold unless there is a history of severe reaction (Grade 3–4 anaphylaxis).  Preliminary data shows 35–40% of infants with diagnosed peanut allergy are tolerant at OFC, allowing for delabelling. This significantly alters long-term food allergy trajectory for these children.  Over the past year, the ADAPT OIT program has been implemented in 12 public paediatric tertiary centres across Australia. The Royal Children’s Hospital in Melbourne is the sole site providing this care in Victoria, but without added funding or infrastructure, demand far exceeds capacity.</description>
    <dc:date>2025-08-01T00:00:00Z</dc:date>
  </item>
  <item rdf:about="http://hdl.handle.net/11434/2392">
    <title>Self-directed vs supervised simulation training in focused cardiac ultrasound: a non-inferiority randomized trial</title>
    <link>http://hdl.handle.net/11434/2392</link>
    <description>Title: Self-directed vs supervised simulation training in focused cardiac ultrasound: a non-inferiority randomized trial
Epworth Authors: Brooks, Kyle S.; McKenzie, Dean
Abstract: Focused cardiac ultrasound (FCU) is increasingly integrated into undergraduate medical curricula, yet traditional training methods face scalability challenges due to limited trainer availability and patient access. Ultrasound simulators offer a potential solution, but the effectiveness of fully self-directed training remains under explored.</description>
    <dc:date>2025-08-01T00:00:00Z</dc:date>
  </item>
  <item rdf:about="http://hdl.handle.net/11434/2391">
    <title>Expanding the Molecular Oncology and Cancer Immunology Biobank: Incorporating patients receiving AuSCT and CAR T-Cell Therapy.</title>
    <link>http://hdl.handle.net/11434/2391</link>
    <description>Title: Expanding the Molecular Oncology and Cancer Immunology Biobank: Incorporating patients receiving AuSCT and CAR T-Cell Therapy.
Epworth Authors: Prince, H. Miles; Johnston, Hayley; Brooks, Niclole; Tan, Charmaine; Hoeper, Olivia; O’Keeffe, Isabelle; Yannakou, Costas
Abstract: In 2018, the Molecular Oncology and Cancer Immunology (MOCI) group established a Biobank study to collect and store samples from Epworth patients with newly diagnosed haematological malignancies. It has since evolved to capture a diverse range of patients with an array of conditions. As Epworth has advanced with new and innovative treatments, our Biobank has expanded its repository to include biospecimens and clinical&#xD;
data from patients undergoing autologous stem cell transplantation (AuSCT) and chimeric antigen receptor (CAR) T-cell therapy. Including these valuable patient cohorts has strengthened the Biobank’s capacity to support future translational research aimed at improving health outcomes for those with haematological malignancies.</description>
    <dc:date>2025-08-01T00:00:00Z</dc:date>
  </item>
  <item rdf:about="http://hdl.handle.net/11434/2390">
    <title>Lessons Learned: Clinicians’ perspectives, knowledge, and attitudes towards a stroke-integrated cardiac rehabilitation program.</title>
    <link>http://hdl.handle.net/11434/2390</link>
    <description>Title: Lessons Learned: Clinicians’ perspectives, knowledge, and attitudes towards a stroke-integrated cardiac rehabilitation program.
Epworth Authors: Machado, Natasha; Sutherland, Edwina; Hill, Bridget; Williams, Gavin; Olver, John; Johnson, Liam
Abstract: Cardiac rehabilitation (CR) is a well-established secondary prevention program for people with cardiovascular disease, including people with heart disease and stroke.1 Yet people with stroke are rarely referred to CR.2&#xD;
Understanding the lived experiences of healthcare professionals involved in a stroke-integrated CR research program may aid the uptake and translation of stroke-integrated CR into routine clinical practice.                       Most clinicians believed stroke-integrated CR was important and had clinical utility. Increased awareness of evidence-based recommendations and the stroke-integrated CR program, and a more flexible and adaptable program may aid uptake and future implementation.</description>
    <dc:date>2025-08-01T00:00:00Z</dc:date>
  </item>
</rdf:RDF>

